Menu
HCEMM is considered first and foremost by the partnership with the European Molecular Biology Laboratory (EMBL) is one of the world’s leading research institutions, and Europe’s flagship laboratory for the life sciences.
HCEMM-EMBL Partnership for Molecular Medicine is EMBL’s fifth remote partnership, a partnership outside the countries where EMBL has its six sites, and its first in Central Europe. The mission of HCEMM is to focus on research in the field of cardiovascular, tumour and inflammatory disease especially affecting older generations and thereby bridging basic to translational research. HCEMM-EMBL Partnership for Molecular Medicine is inspired by the desire of EMBL and its member state Hungary to make sure that EMBL’s research strategy and operational model are implemented on national level. It comprises not only an inter-institutional research initiative, but also serves to secure better integration and participation of national scientific communities into EMBL’s activities, and opportunity for HCEMM to benefit from the EMBL model.
As part of the HCEMM-EMBL Partnership for Molecular Medicine, HCEMM follows the EMBL operational model and principles aiming at scientific excellence and establishing mechanisms for independent, regular scientific evaluation of research activities, scientific integrity and good scientific practice, as well as commitment to international recruitment and significant levels of staff turnover.
Credit: Kinga Lubowiecka/EMBL
Prof. Dr. László Palkovics, the Hungarian Minister for Innovation and Technology, visited the headquarters of EMBL in January, 2020.
The original article can be found:
https://www.embl.org/news/events/hungarian_minister_visiting/
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 739593. HCEMM supported by EU Programme: H2020-EU.4.a. – Teaming of excellent research institutions and low performing RDI regions. Project starting date was 1 April 2017.
